digital therapeutics
-
The outlook for tech-enabled personalized care in healthcare and life sciences
A webinar sponsored by Twilio will share predictions for driving personalized care and engagement in healthcare and life sciences in 2022.
-
Artificial Intelligence, BioPharma
Biofourmis adds $300M to ramp up in virtual care, digital therapy clinical trials
The Series D round of funding makes Biofourmis a unicorn valued at $1.3 billion. CEO and founder Kuldeep Singh Rajput said that the new capital will be used to expand his company’s remote-monitoring technologies and continue development of digital therapeutics, both as companions to traditional drugs and as monotherapies.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
New study shows first FDA-cleared video game treatment for pediatric ADHD improves brain function
In the U.S., EndeavorRx has been cleared to help in improving attention function as measured by computer-based testing in children ages 8-12 years who have primarily inattentive or combined-type ADHD who struggle with maintaining attention.
-
Pear’s digital therapeutic for alcohol use disorder gets breakthrough designation
The company got a breakthrough device designation for its app-based program for alcohol use disorder, reset-A. Pear currently has FDA-cleared digital therapeutics to address opioid use and substance use disorders.
-
Click Therapeutics raises $52M, looks to advance digital therapeutics
Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
-
Startups, Health Services, Health Tech
Investors see promise in digital health — the challenge is adoption
VCs at MedCity INVEST Digital Health said there’s no shortage of interesting digital health companies, even ones that can prove their innovations are effective. The challenge is winning over insurers and physicians, and finding payment models that work.
-
Startup testing video-based treatment for ‘lazy eye’ touts Phase 3 results
Luminopia, a startup with a digital therapeutic for amblyopia, or lazy eye, recently published the results of a phase 3 study showing its TV-based treatment can improve vision in kids’ non-dominant eye. Patients don a headset where images are altered to make them use both eyes.
-
Neuroglee looks to Mayo partnership, digital therapeutics to tackle mild cognitive impairment
Neuroglee recently raised $10 million in funding and struck a partnership with Mayo Clinic. It’s building a digital therapeutic and virtual programs for people with mild cognitive impairment.
-
Big Health tests if insomnia app can help with anxiety, depression
The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
AppliedVR, Curebase to launch five studies of VR for chronic pain
The startup is working with Curebase to launch five clinical trials to test its VR-based therapeutic for chronic pain. They plan to enroll a total of more than 2,000 people.
-
Akili strikes $37.5M licensing deal for another game-based treatment
The company is licensing out technology from Australian digital health company TALi Digital to improve attention in early childhood. Akili will pay $37.5 million, including milestone payments and royalties.
-
Report: Digital health tools maturing as research, funding grows
Consumers and benefits managers have a record number of digital health tools to choose from, according to a new report by the IQVIA Institute for Human Data Science.
-
CEO of digital therapeutics business Freespira talks about its approach to anxiety disorders
Freespira CEO Dean Sawyer said its FDA cleared digital therapeutic is the first that’s proven to significantly reduce or eliminate symptoms of panic attacks, panic disorder, and PTSD, in a single, 28-day treatment episode.
-
MedCity Influencers, Health Tech
Without judgment: How digital therapeutics is destigmatizing mental health treatment
DTx helps reduce mental health stigma that is a barrier for underrepresented populations to receiving mental health care and if developed with intention and within a culturally-responsive framework, DTx won’t judge or discriminate.
-
Pear Therapeutics plans to go public in $1.6B SPAC deal
Digital therapeutics startup Pear Therapeutics struck a deal to go public through a blank-check acquisition that would value the company at $1.6B. But it still faces big challenges in selling its app-based treatments.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
